Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model

Surgery

Volumn 125, Issue 3, 1999, Pages 257-264

  Matsumoto, Gaku ^a   Sunamura, Makoto ^a   Shimamura, Hiromune ^a   Kodama, Tomohiro ^a   Hashimoto, Wataru ^a   Kobari, Masao ^a   Kato, Kazunori ^a   Takeda, Kazuyosi ^a   Yagita, Hideo ^a   Okumura, Ko ^a   Hamada, Hirofumi ^a   Matsuno, Seiki ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; TUMOR VACCINE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENETIC ENGINEERING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VACCINATION;

EID: 0032952107     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70235-7     Document Type: Article

References (34)

1. Golumbeck PT, Lazenby AJ, Levitsky HI, Jaffee EM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete IL-4. Science 1991;254:713-6.
2. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991;146:3074-81.
3. Chan SH, Kobayashi M, Santoli D, Perussian B, Trinchieri G. Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/Il-12): role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992;148:92-8.
4. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK Effect of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 1994;152:2172-9.
5. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
6. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-82.
7. Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W, et al. Cloning and expression of murine IL-12. J Immunol 1992;148:3433-40.
8. Nastala CL, Edington HD, Mckinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in ssociation with IFN-γ production. J Immunol 1994;153:1697-706.
9. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
10. Zou J-P, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFNγ production by anti-tumor T cells. Int Immunol 1995;7:1135-45.
11. Zitvogel L, Tahara H, Robbins P, Storkus W, Clarke M, Lotze MT. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-403.
12. Gately MK, Warrier R, Honasoge S, Carvajal D, Faherty D, Connaughton S, et al. Administration of recombinant IL-12 to normal mouse enhances cytolytic lymphocyte activity and induces production of IFNγ in vivo. Int Immunol 1994;6:157-67.
13. Corbett TH, Griswold D, Roberts B, Peckham J, Schabel F Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay, with a note on carcinogen structure. Cancer Res 1975;35:2434-7.
14. Tahara H, Herbert J-Zeh III, Lotze MT. Fibroblast genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-9.
15. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with IL-12 genes. Eur J Immunol 1995;25:137-46.
16. Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996;56:2531-4.
17. Zitvogel L, Tahara H, Cai Q, Robbins P, Storkus W, Muller G, et al. Construction and characterization of retroviral vectors expressing biologically active human IL-12. Hum Gene Ther 1994;5:1493-506.
18. Jainchill JL, Aaronson S, Todaro G. Murine sarcoma and leukemia viruses: assayusing clonal lines of contact-inhibited mouse cells. J Virol 1969;4:549-53.
19. Wakimoto H, Abe J, Tunoda R, Aoyagi M, Hirakawa K, Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996;56:1828-33.
20. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 1988;85:6460-4.
21. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
22. Colombo MP, Jaenisch R, Wettstein PJ. Integration and expression of retrovirus leads to the expression of a histocompatibility antigen detected by skin graft rejection. Proc Natl Acad Sci USA 1987;84:189-93.
23. Rodolfo M, Bassi C, Salvi C, Parmiani G. Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumor-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumors. Cancer Immunol Immunother 1991;34:53-62.
24. Stuehr DJ, Nathan CF. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989;169:1543-55.
25. Gately MK, Warrier R, Honasoge S, Carvajal D, Faherty D, Connaughton S, et al. Administration of recombinant IL-12 to normal mouse enhances cytolytic lymphocyte activity and induces production of IFN-gammma in vivo. Int Immunol 1994;6:157-67.
26. Wallach D, Fellous M, Revel M. Preferential effect of interferon-γ on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982;299:833-6.
27. Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM, et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996;156:693-9.
28. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK. Role of IFNg in mediating the antitumor efficacy of interleukin-12. J Immunotherapy 1995;17:71-7.
29. Gansbacher B, Zeier K, Daniels B, Cronin K, Bennerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
30. Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L, et al. Low doses of IL4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990;145:3136-43.
31. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-86.
32. Gansbacher B, Bennerji R, Daniels B, Zeier K, Cronin K, Gilboa E. Retroviral vector-mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
33. Cavallo F, Giovarelli M, Gulino A, Stoppacciaro A, Modesti A, Forni G. Role of neutrophhils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992;149:3627-35.
34. Tepper RI, Pattengal PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.